The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second $500,000 grant to NRG Therapeutics supporting more research into its potential disease-modifying therapy for Parkinson’s disease. The new funding comes after the successful completion of a previous MJFF-funded project that set out to investigate how NRG’s small…
Among several atypical antipsychotics, Nuplazid (pimavanserin) seems to be the most effective at easing Parkinson’s disease psychosis (PDP) while sparing motor function, according to a review study. Clozapine, used off-label in people with Parkinson’s, also helped, but its effect was not as large and patients were more…
Deep brain stimulation (DBS) is more effective at easing nonmotor symptoms and improving life quality for people with the postural instability and gait disturbance (PIGD) subtype of Parkinson’s disease than for those with the tremor-dominant (TD) subtype, a study showed. While previous studies have suggested different effects of…
LisCure Biosciences is teaming up with Celltrion to identify and develop oral therapies targeting the gut microbiome — the population of microorganisms living in the gastrointestinal tract —for people with Parkinson’s disease, the company announced. Under the collaboration, the South Korean companies aim to develop orally available live biotherapeutic…
Certain regulators of protein balance are suppressed in people with sporadic Parkinson’s disease and in those with familial disease linked to G2019S, the most common disease-causing LRRK2 gene variant, according to a study of patient-derived skin cells. These findings suggest shared underlying mechanisms between both types of Parkinson’s,…
People with Parkinson’s disease are at a higher risk of simultaneous autoimmune diseases where the immune system erroneously attacks the body, according to a review study. Pooled data from multiple studies showed a significantly increased risk of Parkinson’s combined with either bullous pemphigoid, a rare skin condition, inflammatory bowel…
Older Parkinson’s patients undergoing deep brain stimulation (DBS), those in their 60s and 70s at the time of the surgical procedure, as well as those diagnosed at older ages are at a higher risk of death over the following years, according to a nationwide study in South Korea.
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild cognitive impairment (MCI) due to Parkinson’s disease. The trial is recruiting Parkinson’s patients at 16 sites across the U.S. Dubbed PRECEDENT (NCT05318937), it’s designed to investigate SAGE-718’s…
People with Parkinson’s disease have a nearly twofold higher risk of developing osteoporosis, a chronic condition marked by increased bone fragility, than healthy people, a study showed. Besides identifying for the first time Parkinson’s as an independent risk factor for osteoporosis, the researchers found five genes with diagnostic and…
Levels of the GFAP protein in blood are significantly higher in Parkinson’s disease patients with cognitive impairment — particularly those with dementia — compared with healthy people, a new study shows. According to researchers, blood GFAP levels could accurately identify Parkinson’s patients with mild cognitive impairment (MCI) who ended…
Get regular updates to your inbox.
